Drug Trial Radar · NCT04943068
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
193
Actual
Start
May 10, 2021
Primary completion
May 16, 2023
Study completion May 16, 2023
Sponsor
- Lead sponsor
- Kwang Dong Pharmaceutical co., ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
Conditions
- Hypoactive Sexual Desire Disorder
Interventions
BremelanotideDrug
Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector.
PlaceboDrug
Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to End of Study in the desire domain from the FSFITime frame: Baseline up to End of Study(8weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.